Janux Therapeutics Inc JANX

Healthcare Biotechnology

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

NDAQ:JANX - Post by User

Janux Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by MikeTesteron Aug 02, 2024 12:17pm

45 Views

Post# 36161123

Janux Therapeutics, Inc. (NASDAQ:JANX): A Promising Biopharm

https://beyondspx.com/2024/07/31/janux-therapeutics-inc-nasdaqjanx-a-promising-biopharmaceutical-company-developing-innovative-tumor-activated-immunotherapies/

<< Previous

Bullboard Posts

Next >>

NTG Clarity Networks' growth story continues with $22M contract